HU9601301D0 - Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors - Google Patents

Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors

Info

Publication number
HU9601301D0
HU9601301D0 HU9601301A HU9601301A HU9601301D0 HU 9601301 D0 HU9601301 D0 HU 9601301D0 HU 9601301 A HU9601301 A HU 9601301A HU 9601301 A HU9601301 A HU 9601301A HU 9601301 D0 HU9601301 D0 HU 9601301D0
Authority
HU
Hungary
Prior art keywords
donors
treatment
nitric oxide
oxide synthase
climacteric disorders
Prior art date
Application number
HU9601301A
Other languages
English (en)
Other versions
HUT74459A (en
Inventor
Radoslaw Bukowski
Kristof Chwalisz
Robert E Garfield
Chandra Yallampalli
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HU9601301D0 publication Critical patent/HU9601301D0/hu
Publication of HUT74459A publication Critical patent/HUT74459A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU9601301A 1993-11-16 1994-11-17 Pharmaceutical compositions containing nitric oxide synthase substrates and/or donors and steroides using them for treatment of climacteric disorders HUT74459A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/153,345 US5595970A (en) 1993-07-16 1993-11-16 Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors

Publications (2)

Publication Number Publication Date
HU9601301D0 true HU9601301D0 (en) 1996-07-29
HUT74459A HUT74459A (en) 1996-12-30

Family

ID=22546812

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9601301A HUT74459A (en) 1993-11-16 1994-11-17 Pharmaceutical compositions containing nitric oxide synthase substrates and/or donors and steroides using them for treatment of climacteric disorders

Country Status (16)

Country Link
US (2) US5595970A (hu)
EP (1) EP0730445A1 (hu)
JP (1) JPH09505069A (hu)
KR (1) KR960705554A (hu)
CN (1) CN1135177A (hu)
AU (1) AU8144694A (hu)
BR (1) BR9408062A (hu)
CA (1) CA2176727A1 (hu)
CZ (1) CZ140096A3 (hu)
FI (1) FI962110A (hu)
HU (1) HUT74459A (hu)
NO (1) NO961994L (hu)
NZ (1) NZ276106A (hu)
PL (1) PL178130B1 (hu)
SK (1) SK63496A3 (hu)
WO (1) WO1995013800A1 (hu)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE69535607T2 (de) * 1994-05-27 2008-07-10 Strakan International Ltd. Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
AU771012B2 (en) * 1996-05-07 2004-03-11 Board Of Regents, The University Of Texas System Improvement of implantation rates after in vitro fertilization
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
WO1998040076A1 (en) * 1997-03-10 1998-09-17 Schering Aktiengesellschaft Compositions for the treatment of climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with partial estrogen antagonists
US20030114515A1 (en) * 1997-04-10 2003-06-19 Kaesemeyer Wayne H. Therapeutic mixture of HMG-COA reductase inhibitors
EP0998274B1 (en) * 1997-06-23 2006-01-18 Cellegy Pharmaceuticals, Inc Microdose therapy of vascular conditions by no donors
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6645954B2 (en) 1998-04-09 2003-11-11 Multimed Limited Compositions comprising ethisterone or its derivatives
GB9807809D0 (en) * 1998-04-09 1998-06-10 Multimed Ltd Compositions comprising ethisterone or its derivatives
JP2002539257A (ja) * 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド 薬剤の脳内生物学的利用率の増加
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
KR20040052489A (ko) 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
KR20050083827A (ko) * 2002-10-24 2005-08-26 이노스 파마슈티칼스, 인코포레이티드 서방성 ｌ-아르기닌 포뮬레이션 및 이의 제조방법 및 용도
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
US20040253326A1 (en) * 2003-02-25 2004-12-16 Mesko Charles A. Composition for increasing levels of hormones and a method for preparation of said composition
JP2007521324A (ja) * 2003-09-29 2007-08-02 エノス ファーマシューティカルズ， インク． 徐放性ｌ−アルギニン調合物並びにその製造法及び使用法
US20060067961A1 (en) * 2004-09-30 2006-03-30 Kimberly-Clark Worldwide,Inc. Skin cooling compositions
US20060067962A1 (en) * 2004-09-30 2006-03-30 Kimberly-Clark Worldwide, Inc. Skin cooling compositions
DE102008040479A1 (de) 2007-07-23 2009-02-05 Denso Corp., Kariya-shi Kraftstoffzufuhrvorrichtung
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150313956A1 (en) * 2014-05-05 2015-11-05 Napier Consulting Llc Compositions and methods for hair growth
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2021187789A (ja) * 2020-06-01 2021-12-13 株式会社リアルメイト ヒートショックプロテイン誘導剤、一酸化窒素産生促進剤、抗更年期障害剤、抗加齢剤、化粧品および食品または飲料

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy

Also Published As

Publication number Publication date
HUT74459A (en) 1996-12-30
CN1135177A (zh) 1996-11-06
NO961994D0 (no) 1996-05-15
AU8144694A (en) 1995-06-06
CA2176727A1 (en) 1995-05-26
FI962110A0 (fi) 1996-05-17
JPH09505069A (ja) 1997-05-20
BR9408062A (pt) 1996-11-24
FI962110A (fi) 1996-07-15
SK63496A3 (en) 1997-03-05
US5595970A (en) 1997-01-21
US5958878A (en) 1999-09-28
PL314466A1 (en) 1996-09-16
PL178130B1 (pl) 2000-03-31
KR960705554A (ko) 1996-11-08
WO1995013800A1 (en) 1995-05-26
EP0730445A1 (en) 1996-09-11
NO961994L (no) 1996-07-16
CZ140096A3 (en) 1996-09-11
NZ276106A (en) 1998-05-27

Similar Documents

Publication Publication Date Title
HU9601301D0 (en) Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
GB2283179B (en) Nitric oxide treatment
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
HK1007516A1 (en) Catheters and method of manufacture
AU4777596A (en) Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
EP0534474A3 (en) Si substrate and method of processing the same
AU6693898A (en) Composition for the treatment of male climacteric disorders with nitric oxide s ynthase substrates and/or donors, in combination with androgens and/or arom atase inhibitors
AU3519893A (en) Antitumor compositions and methods of treatment
AU3878895A (en) Use of nitric oxide donors in medicine
EP0707050A3 (en) Pigment containing a titanium suboxide and process for its preparation
AU1209995A (en) Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
AU6160594A (en) Diabetes prevention and treatment
AU6528494A (en) Nitric oxide combination therapy
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
EP0688225A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING SUPPLEMENT ACTIVATION
AU3737289A (en) Agent for treating pancreatitis or the like
AU1097892A (en) Process and installation for the treatment of steel-mill slag
GB9321679D0 (en) Treatment of substrates
EP0893123A4 (en) MEANS OF PREVENTIVE AND CURATIVE TREATMENT OF CONDITIONS RELATED TO DIFFERENT FORMS OF AGING OF THE ORGANISM
IL128095A0 (en) Formulation for the treatment and/or prophylaxis of dementia
HU9403656D0 (en) Methods of inhibiting obsessive-compulsive and consumptive disorders
HU263U (en) External catheter and applicator
AU6694298A (en) Compositions for the treatment of climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with partial estrogen anta gonists
HUP9902574A3 (en) Medicaments containing nitric oxide synthase substrates and/or nitric oxide donors and which applicable for use of incontinence
AU2846289A (en) Agent for the treatment of bradycardia and bradyarrythmia

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal